Search results for "48"

showing 10 items of 1388 documents

Spectroscopy of 253No and its daughters

2011

Abstract New high-statistics data have been obtained on the decay properties of 253 No and its daughters using the reaction 207 Pb( 48 Ca, 2n) 253 No. This was made possible thanks to an improved transmission of fusion–evaporation residues through the VASSILISSA recoil separator and an increased efficiency of the GABRIELA detector setup. The decay schemes of 253 No and 249 Fm have been revisited. The known level scheme of 249 Fm has been confirmed, including a new level at 669 keV excitation energy. The observation of L X-rays in coincidence with the α decay of 249 Fm gives additional support to the ground-state configuration of 1 / 2 + [ 631 ] instead of 5 / 2 + [ 622 ] for 245 Cf. In both…

Nuclear and High Energy PhysicsPhotonmultipolaritiesNUCLEAR REACTIONS 207Pb(48CaPopulationElectron[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]01 natural sciencesCoincidenceSpectral lineNuclear physics0103 physical sciencesmeasured Eαπ010306 general physicsSpectroscopyeducationPhysics2n)I (ce)education.field_of_study3n)Decay scheme010308 nuclear & particles physicsα(ce)-coindeduced levelsαγT1/2Qα. 253No249FmE(ce)Atomic physics(48CaE = 220 MeVExcitationdeduced ICCs
researchProduct

Measurement of Kμ30 form factors

2007

Abstract This Letter reports on a new high precision measurement of the form factors of the K L → π ± μ ∓ ν μ decay. The data sample of about 2.3 × 10 6 events was recorded in 1999 by the NA48 experiment at CERN. Studying the Dalitz plot density we measured a linear, λ + ′ = ( 20.5 ± 2.2 stat ± 2.4 syst ) × 10 −3 , and a quadratic, λ + ″ = ( 2.6 ± 0.9 stat ± 1.0 syst ) × 10 −3 term in the power expansion of the vector form factor. No evidence was found for a second order term for the scalar form factor; the linear slope was determined to be λ 0 = ( 9.5 ± 1.1 stat ± 0.8 syst ) × 10 −3 . Using a linear fit our results were: λ + = ( 26.7 ± 0.6 stat ± 0.8 syst ) × 10 −3 and λ 0 = ( 11.7 ± 0.7 s…

Nuclear physicsPhysicsNuclear and High Energy Physics010308 nuclear & particles physics0103 physical sciencesForm factor (quantum field theory)Dalitz plotNA48 experiment010306 general physics01 natural sciencesPhysics Letters B
researchProduct

Kotoutumiskoulutuksen opetussuunnitelman perusteet kuvaa tavoitettaan osallisuutta epämääräisesti ja kapeasti

2023

Kotoutumiskoulutuksen uudessa perusteasiakirjassa korostuu osallisuuden käsite. Se jää kuitenkin määrittelemättä: osallisuuteen viitataan sekä kapearajaisesti työmarkkinaosallisuutena että epäsuorasti niin, että käsitteen varsinainen merkitys jää avoimeksi. Tutkimuskirjallisuudessa osallisuus edellyttää laaja-alaista sosiaalis-yhteiskunnallista kuulumista ja yhdenvertaisuutta. nonPeerReviewed

Näkökulmia politiikkaanopetussuunnitelmat [http://www.yso.fi/onto/yso/p5140]osallisuus [http://www.yso.fi/onto/yso/p5164]kotoutumiskoulutuskotouttaminen (maahanmuuttajat)kotoutuminenintegraatiotyövoimakoulutus [http://www.yso.fi/onto/yso/p4160]yhdenvertaisuusosallistaminenosallistuminen [http://www.yso.fi/onto/yso/p10727]osallisuuskotoutumiskoulutus [http://www.yso.fi/onto/yso/p25048]integraatio [http://www.yso.fi/onto/yso/p1731]opetussuunnitelmatosallistuminen
researchProduct

Characterization of softwood and hardwood lignoboost kraft lignins with emphasis on their antioxidant activity

2014

Fractionation of softwood and hardwood LignoBoost kraft lignins, using sequential extraction with organic solvents of increasing hydrogen-bonding ability (dichloromethane, n-propanol, and methanol), was carried out. Using SEC, analytical pyrolysis, FTIR and UV/VIS spectroscopy, and chemical analytical methods, four fractions were obtained and characterized in terms of their yield, composition, functionality, lignin structural features, and antioxidant properties. In tests with free radicals (ABTS●+, DPPH●, O2●-) and the ORAC (oxygen radical absorbance capacity) assay, the high radical scavenging capacity of the lignin’s soluble fractions was demonstrated. The antioxidant activity of the fra…

ORAC assayEnvironmental EngineeringSoftwoodABTSOxygen radical absorbance capacityLignoBoost kraft ligninDPPHAntioxidant propertieslcsh:Biotechnologytechnology industry and agricultureBioengineeringmacromolecular substancesFractionationDPPH●chemistry.chemical_compoundchemistryABTS●+lcsh:TP248.13-248.65HardwoodOrganic chemistryLigninSolvent fractionationWaste Management and DisposalKraft paperO2●- assays
researchProduct

Gatekeeper of pluripotency: A common Oct4 transcriptional network operates in mouse eggs and embryonic stem cells

2011

Abstract Background Oct4 is a key factor of an expanded transcriptional network (Oct4-TN) that governs pluripotency and self-renewal in embryonic stem cells (ESCs) and in the inner cell mass from which ESCs are derived. A pending question is whether the establishment of the Oct4-TN initiates during oogenesis or after fertilisation. To this regard, recent evidence has shown that Oct4 controls a poorly known Oct4-TN central to the acquisition of the mouse egg developmental competence. The aim of this study was to investigate the identity and extension of this maternal Oct4-TN, as much as whether its presence is circumscribed to the egg or maintained beyond fertilisation. Results By comparing …

Octamer Transcription Factor-3lcsh:QH426-470lcsh:BiotechnologycellsGene regulatory networkDown-RegulationBiologyTranscriptomeMicelcsh:TP248.13-248.65GeneticsInner cell massAnimalsGene Regulatory NetworksEmbryonic Stem Cellsreproductive and urinary physiologyOligonucleotide Array Sequence AnalysisGeneticsGene Expression ProfilingfungiEmbryoEmbryonic stem cellGene expression profilinglcsh:GeneticsMultigene FamilyCancer cellembryonic structuresOocytesFemalebiological phenomena cell phenomena and immunityFunction and Dysfunction of the Nervous SystemOctamer Transcription Factor-3Research ArticleBiotechnologyBMC Genomics
researchProduct

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…

2013

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…

OncologyMaleIndolesPyridinesSettore MED/06 - Oncologia MedicaSU11248MedizinPiperazineslaw.inventionchemistry.chemical_compoundRandomized controlled triallawClinical endpointSunitinibTreatment Failureregorafenib; gastrointestinal stromal tumours; imatinib and sunitinibGastrointestinal Neoplasmseducation.field_of_studyGiSTSunitinibKITAge-related aspects of cancer Quality of hospital and integrated care [ONCOL 2]General MedicineMiddle AgedSurvival RateBenzamidesImatinib MesylateFemaleADJUVANT IMATINIBTYROSINE KINASE INHIBITORColorectal NeoplasmsLife Sciences & Biomedicinemedicine.drugGROWTH-FACTORmedicine.medical_specialtyGastrointestinal Stromal TumorsPopulationMESYLATEAntineoplastic AgentsIMATINIBArticleMECHANISMSMedicine General & InternalDouble-Blind MethodTranslational research [ONCOL 3]General & Internal MedicineRegorafenibInternal medicineMANAGEMENTmedicineHumansPyrroleseducationProtein Kinase InhibitorsAgedScience & TechnologyGASTROINTESTINAL STROMAL TUMOURSimatinib and sunitinibMUTATIONSbusiness.industryPhenylurea CompoundsGIST regorafenib imatinib sunitinib phase III trialSurgeryClinical trialImatinib mesylatePyrimidineschemistryregorafenibbusinessRESISTANCE
researchProduct

The New TNM Staging System for Thyroid Cancer and the Risk of Disease Downstaging

2018

In October 2016 the American Joint Committee on Cancer (AJCC) published the 8th edition of the AJCC/TNM cancer staging system and it has been introduced in clinical practice since 1st January 2018. The effect of most of the changes in the new edition was the downstaging of a significant number of patients into lower stages, reflecting their low risk of thyroid cancer-related death. One of the most relevant modification refers to the role of the microscopic extra-thyroidal tumor invasion, which is no longer considered as criterion for the classification of T3 tumors. With the present study we want to assess the impact of the changes of the new staging system and therefore we analyzed or casi…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismDownstaging; Staging system; Thyroid cancer; TNM 2018; Tumor invasion; Endocrinology Diabetes and Metabolism030209 endocrinology & metabolismAggressive diseaseDiseaseTNM staging systemlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinethyroid cancerstaging systemMedicineStaging systemThyroid cancerCancer stagingOriginal Researchlcsh:RC648-665TNM 2018business.industryThyroidCancerdownstagingtumor invasionmedicine.diseaseDiabetes and Metabolismmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessFrontiers in Endocrinology
researchProduct

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk

2019

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male brea…

Oncologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismPALB2Diseasemale breast cancerHyperestrogenismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerInternal medicineGenotypeCYP17A1Internal MedicineGenetic predispositionMedicine030212 general & internal medicineskin and connective tissue diseasesEstrogen Receptor Statusmale breast cancer; CYP17A1; CYP1B1; polymorphisms; male breast cancer risklcsh:RC648-665business.industryResearchmedicine.diseasemale breast cancer risk030220 oncology & carcinogenesisMale breast cancerCYP1B1medicine.symptombusinesspolymorphismsEndocrine Connections
researchProduct

Identification and expression of the 11β‐steroid hydroxylase from Cochliobolus lunatus in Corynebacterium glutamicum

2019

Hydroxylation of steroids has acquired special relevance for the pharmaceutical industries. Particularly, the 11β-hydroxylation of steroids is a reaction of biotechnological importance currently carried out at industrial scale by the fungus Cochliobolus lunatus. In this work, we have identified the genes encoding the cytochrome CYP103168 and the reductase CPR64795 of C. lunatus responsible for the 11β-hydroxylase activity in this fungus, which is the key step for the preparative synthesis of cortisol in industry. A recombinant Corynebacterium glutamicum strain harbouring a plasmid expressing both genes forming a synthetic bacterial operon was able to 11β-hydroxylate several steroids as subs…

Operonlcsh:BiotechnologyGenetic VectorsGene ExpressionBioengineeringReductaseHydroxylationApplied Microbiology and BiotechnologyBiochemistryCorynebacterium glutamicumHydroxylation03 medical and health scienceschemistry.chemical_compoundPlasmidBiotransformationAscomycotalcsh:TP248.13-248.65Cloning MolecularResearch ArticlesBiotransformation030304 developmental biology0303 health sciencesbiology030306 microbiologyCochliobolus lunatusbiology.organism_classificationRecombinant ProteinsCorynebacterium glutamicumchemistryBiochemistrySteroid hydroxylaseSteroid 11-beta-HydroxylasebacteriaSteroidsBiotechnologyResearch ArticlePlasmidsMicrobial Biotechnology
researchProduct